相关临床试验
236
9 进行中
药物批准
17
批准总数
监管机构
1
监管机构数
成立时间
1949
进行中（未招募）
7
3.0%
Available
1
0.4%
已完成
188
79.7%
尚未招募
2
0.8%
招募中
18
7.6%
暂停
1
0.4%
终止
18
7.6%
撤回
1
0.4%
- A pooled analysis of three clinical trials identified higher serum TRACP-5b levels and lower Bristol Stool Form Scale scores as independent predictors of requiring higher tenapanor doses in dialysis patients with hyperphosphatemia. - Elevated TRACP-5b, a marker of bone resorption, suggests that greater bone-derived phosphorus release may attenuate tenapanor's phosphorus-lowering effect, necessitating dose escalation. - Patients prone to constipation were more likely to tolerate higher tenapanor doses, likely due to the drug's osmotic, stool-softening mechanism of action. - The findings support incorporating bone turnover and bowel habit assessments into routine clinical evaluation to guide individualized tenapanor dosing.
- Kura Oncology has dosed first patients in KOMET-015, a Phase 1 trial evaluating ziftomenib in combination with imatinib for advanced gastrointestinal stromal tumors (GIST) after imatinib failure. - Preclinical studies show the combination provides robust antitumor activity in both imatinib-sensitive and imatinib-resistant GIST models through a synthetic lethal mechanism targeting tumor vulnerabilities. - With approximately 60% of GIST patients developing imatinib resistance within two years, this novel menin inhibitor combination represents a potential breakthrough for the estimated 4,000-6,000 new GIST cases diagnosed annually in the U.S.
- AstraZeneca's Fasenra (benralizumab) has been approved in the EU for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). - The approval was based on the Phase III MANDARA trial, which demonstrated comparable remission rates between Fasenra and mepolizumab. - Data from the MANDARA trial also showed that 41% of Fasenra-treated patients were able to fully taper off oral corticosteroids (OCS). - Fasenra offers a convenient, single-monthly injection, providing a much-needed treatment option for EGPA patients in Europe.
